The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Open accessPublished version of a preprint
Abstract
Functional genomics approaches can overcome limitations-such as the lack of identification of robust targets and poor clinical efficacy-that hamper cancer drug development. Here we performed genome-scale CRISPR-Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the MSI that often leads to cancer simultaneously makes the inhibition of Werner syndrome ATP-dependent helicase (WRN) lethal to the tumor cells62,63”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [62]
In the citing paper
“''Fitness Scores'' that were calculated from large-scale genome-wide CRISPR/Cas9 screens across 31 independent CRC cell lines and represent a quantitative measure of the reduction of cell viability elicited by a gene inactivation via CRISPR/Cas9 (https://score.depmap.sanger.ac.uk) (Behan et al., 2019;van der Meer et al., 2019).”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as Behan et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“Most patients however do not benefit from such targeted therapies in part due to limited knowledge of candidate targets(Zehir et al. 2017).”
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Cited by
Sorted by citations
Items 101–200 of 999
OGEE v3: Online GEne Essentiality database with increased coverage of organisms and human cell lines
Gurumayum, S., Jiang, P., Hao, X., Campos, T. D. L., Young, N. D., Korhonen, P. K., Gasser, R. B., Bork, P., Zhao, X., He, L., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa884 · Cited by 92
Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
Fowler, J. C., King, C., Bryant, C., Hall, M. W. J., Sood, R. K., Ong, S. H., Earp, E., Fernández‐Antorán, D., Koeppel, J., Dentro, S. C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1092 · Cited by 95
canSAR: update to the cancer translational research and drug discovery knowledgebase
Mitsopoulos, C., Micco, P. D., Villasclaras-Fernández, E. D., Dolciami, D., Holt, E., Mica, I. L., Coker, E. A., Tym, J. E., Campbell, J., Che, K. H., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1059 · Cited by 94
Singh, S. V., Quarni, W., Goralski, M., Wan, S., Jin, H., de Velde, L.-A. V., Fang, J., Wu, Q., Abu‐Zaid, A., Wang, T., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj5405 · Cited by 87
Neurofibromin and suppression of tumorigenesis: beyond the GAP
Mo, J., Moye, S. L., McKay, R. M., & Le, L. Q. (2022) · Oncogene · doi:10.1038/s41388-021-02156-y · Cited by 95
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer
Dieter, S. M., Siegl, C., Codó, P. L., Huerta, M., Ostermann-Parucha, A. L., Schulz, E., Zowada, M. K., Martin, S., Laaber, K., Nowrouzi, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109394 · Cited by 95
Pan, M., Wright, W. C., Chapple, R. H., Zubair, A., Sandhu, M., Batchelder, J. E., Huddle, B. C., Low, J. A., Blankenship, K., Wang, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26640-x · Cited by 93
Paralog buffering contributes to the variable essentiality of genes in cancer cell lines
De Kegel, B., & Ryan, C. J. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008466 · Cited by 92
Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity
Caruso, S., O’Brien, D. R., Cleary, S. P., Roberts, L. R., & Zucman‐Rossi, J. (2020) · Hepatology · doi:10.1002/hep.31394 · Cited by 96
OCA-T1 and OCA-T2 are coactivators of POU2F3 in the tuft cell lineage
Wu, X., He, X., Ipsaro, J. J., Huang, Y., Preall, J. B., Ng, D., Shue, Y. T., Sage, J., Egeblad, M., Joshua‐Tor, L., et al. (2022) · Nature · doi:10.1038/s41586-022-04842-7 · Cited by 93
ADAR and Immune Silencing in Cancer
Herbert, A. G. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.03.004 · Cited by 90
Base editing screens map mutations affecting interferon-γ signaling in cancer
Coelho, M. A., Cooper, S., Strauß, M. E., Karakoç, E., Bhosle, S. G., Gonçalves, E., Picco, G., Burgold, T., Cattaneo, C. M., Veninga, V., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.009 · Cited by 94
Self-citationCRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives
Chan, Y.-T., Lu, Y., Wu, J., Zhang, C., Tan, H., Bian, Z., Wang, N., & Feng, Y. (2022) · Theranostics · doi:10.7150/thno.71144 · Cited by 93
Shimada, K., Bachman, J. A., Muhlich, J. L., & Mitchison, T. J. (2021) · eLife · doi:10.7554/elife.57116 · Cited by 88
Revolutionizing DNA repair research and cancer therapy with CRISPR–Cas screens
Awwad, S. W., Serrano-Benítez, A., Thomas, J. C., Gupta, V., & Jackson, S. P. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00571-x · Cited by 93
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Govindarajan, M., Wohlmuth, C., Waas, M., Bernardini, M. Q., & Kislinger, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00971-6 · Cited by 89
Wu, J., Li, H., Shi, M., Zhu, Y., Ma, Y., Zhong, Y., Xiong, C., Chen, H., & Peng, C. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1334-5 · Cited by 86
Minimal genome-wide human CRISPR-Cas9 library
Gonçalves, E., Thomas, M., Behan, F. M., Picco, G., Pacini, C., Allen, F. R., Vinceti, A., Sharma, M., Jackson, D. A., Price, S., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02268-4 · Cited by 87
Self-citationUbiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
Simoneau, A., Engel, J. L., Bandi, M. L., Lazarides, K., Liu, S., Meier, S. R., Choi, A. H., Zhang, H., Shen, B., Martires, L. C. M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0409 · Cited by 84
Brosh, R. M., & Matson, S. W. (2020) · Genes · doi:10.3390/genes11030255 · Cited by 93
Scavone, F., Gumbin, S. C., Rosa, P. A. D., & Kopito, R. R. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220340120 · Cited by 85
The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications’ door
Talotta, F., Casalino, L., & Verde, P. (2020) · Oncogene · doi:10.1038/s41388-020-1306-4 · Cited by 84
Predicting and characterizing a cancer dependency map of tumors with deep learning
Chiu, Y.-C., Zheng, S., Wang, L.-J., Iskra, B. S., Rao, M. K., Houghton, P. J., Huang, Y., & Chen, Y. (2021) · Science Advances · doi:10.1126/sciadv.abh1275 · Cited by 84
“Recently, the Cancer Dependency Map (DepMap) projects of the Broad Institute (4–6) and Wellcome Sanger Institute (7) performed genome-wide CRISPR-Cas9 knockout screens in extensive collections of CCLs.”
BackgroundMethodInfluentialStructure–function analysis of the SHOC2–MRAS–PP1C holophosphatase complex
Kwon, J. J., Hajian, B., Bian, Y., Young, L. C., Amor, A. J., Fuller, J. R., Fraley, C. V., Sykes, A. M., So, J., Pan, J., et al. (2022) · Nature · doi:10.1038/s41586-022-04928-2 · Cited by 79
A benchmark of algorithms for the analysis of pooled CRISPR screens
Bodapati, S., Daley, T., Lin, X., Zou, J., & Qi, L. S. (2020) · Genome biology · doi:10.1186/s13059-020-01972-x · Cited by 81
Mutational signatures are markers of drug sensitivity of cancer cells
Levatić, J., Salvadores, M., Fuster‐Tormo, F., & Supek, F. (2022) · Nature Communications · doi:10.1038/s41467-022-30582-3 · Cited by 79
Microsatellite instability: A 2024 update
Yamamoto, H., Watanabe, Y., Arai, H., Umemoto, K., Tateishi, K., & Sunakawa, Y. (2024) · Cancer Science · doi:10.1111/cas.16160 · Cited by 88
CRISPR–Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications
Kolanu, N. D. (2024) · Global Medical Genetics · doi:10.1055/s-0044-1785234 · Cited by 93
Wnts and the hallmarks of cancer
Zhong, Z., Yu, J., Virshup, D. M., & Madan, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09887-6 · Cited by 81
Complex synthetic lethality in cancer
Ryan, C. J., Devakumar, L. J. P. S., Pettitt, S. J., & Lord, C. J. (2023) · Nature Genetics · doi:10.1038/s41588-023-01557-x · Cited by 82
DNAJC9 integrates heat shock molecular chaperones into the histone chaperone network
Hammond, C. M., Bao, H., Hendriks, I. A., Carraro, M., García-Nieto, A., Liu, Y., Reverón-Gómez, N., Spanos, C., Chen, L., Rappsilber, J., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.041 · Cited by 79
A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas
Cervia, L. D., Shibue, T., Borah, A. A., Gaeta, B., He, L., Leung, L., Li, N., Moyer, S. M., Shim, B. H., Dumont, N., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1230 · Cited by 77
Deep learning of pharmacogenomics resources: moving towards precision oncology
Chiu, Y., Chen, H.-I. H., Gorthi, A., Mostavi, M., Zheng, S., Huang, Y., & Chen, Y. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz144 · Cited by 80
CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer
Azangou‐Khyavy, M., Ghasemi, M., Khanali, J., Boroomand-Saboor, M., Jamalkhah, M., Soleimani, M., & Kiani, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02062 · Cited by 80
Population Dynamics in Cell Death: Mechanisms of Propagation
Riegman, M., Bradbury, M. S., & Overholtzer, M. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.008 · Cited by 75
tRNA-derived small RNAs in human cancers: roles, mechanisms, and clinical application
Zhou, M., He, X., Zhang, J., Mei, C., Zhong, B., & Ou, C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01992-2 · Cited by 79
Hallmarks of artificial intelligence contributions to precision oncology
Chang, T., Park, S., Schäffer, A. A., Jiang, P., & Ruppin, E. (2025) · Nature Cancer · doi:10.1038/s43018-025-00917-2 · Cited by 83
Mapping the multiscale structure of biological systems
Schaffer, L. V., & Ideker, T. (2021) · Cell Systems · doi:10.1016/j.cels.2021.05.012 · Cited by 75
Lazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3440 · Cited by 74
Self-citationSynthetic lethal strategies for the development of cancer therapeutics
Ngoi, N. Y. L., Gallo, D., Torrado, C., Nardo, M., Durocher, D., & Yap, T. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00966-z · Cited by 81
Genome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
Functional Genomics for Cancer Drug Target Discovery
Haley, B., & Roudnicky, F. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.006 · Cited by 75
A versatile, high-efficiency platform for CRISPR-based gene activation
Heidersbach, A. J., Dorighi, K. M., Gomez, J. A., Jacobi, A. M., & Haley, B. (2023) · Nature Communications · doi:10.1038/s41467-023-36452-w · Cited by 72
Salvadores, M., Fuster‐Tormo, F., & Supek, F. (2020) · Science Advances · doi:10.1126/sciadv.aba1862 · Cited by 70
The human VRK1 chromatin kinase in cancer biology
Campillo‐Marcos, I., García-González, R., Navarro-Carrasco, E., & Lazo, P. A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.032 · Cited by 69
Wilding, B., Woelflingseder, L., Baum, A., Chylinski, K., Vainorius, G., Gibson, N. J., Waizenegger, I. C., Gerlach, D., Augsten, M., Spreitzer, F., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0306 · Cited by 78
Bhat, S., Palepu, K., Hong, L., Mao, Y., Ye, T., Iyer, R., Zhao, L., Chen, T., Vincoff, S., Watson, R., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr8638 · Cited by 96
PTM-Mamba: a PTM-aware protein language model with bidirectional gated Mamba blocks
Peng, F. Z., Wang, C.-T., Chen, T., Schussheim, B., Vincoff, S., & Chatterjee, P. (2025) · Nature Methods · doi:10.1038/s41592-025-02656-9 · Cited by 32
High-throughput PRIME-editing screens identify functional DNA variants in the human genome
Ren, X., Yang, H., Nierenberg, J. L., Sun, Y., Chen, J., Beaman, C., Pham, T., Nobuhara, M., Takagi, M. A., Narayan, V., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.11.021 · Cited by 70
Connecting chemistry and biology through molecular descriptors
Fernández‐Torras, A., Comajuncosa-Creus, A., Duran‐Frigola, M., & Aloy, P. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.09.001 · Cited by 74
Sun, M., Yue, T., Wang, C., Fan, Z., Gazit, E., & Du, J. (2022) · ACS Nano · doi:10.1021/acsnano.2c01407 · Cited by 69
Phadnis, V. V., Snider, J. D., Varadharajan, V., Ramachandiran, I., Deik, A., Lai, Z. W., Kunchok, T., Eaton, E. N., Sebastiany, C., Lyakisheva, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113023 · Cited by 73
Target sequence-conditioned design of peptide binders using masked language modeling
Chen, T., Quinn, Z., Dumas, M., Peng, C. Y., Hong, L., Lopez-Gonzalez, M., Mestre, A. A., Watson, R., Vincoff, S., Zhao, L., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02761-2 · Cited by 90
Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines
Kegel, B. D., Quinn, N., Thompson, N., Adams, D. J., & Ryan, C. J. (2021) · Cell Systems · doi:10.1016/j.cels.2021.08.006 · Cited by 67
The Fra-1/AP-1 Oncoprotein: From the “Undruggable” Transcription Factor to Therapeutic Targeting
Casalino, L., Talotta, F., Cimmino, A., & Verde, P. (2022) · Cancers · doi:10.3390/cancers14061480 · Cited by 67
High-throughput functional evaluation of human cancer-associated mutations using base editors
Kim, Y., Lee, S., Cho, S., Park, J., Chae, D., Park, T., Minna, J. D., & Kim, S. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01276-4 · Cited by 66
Wang, J., Xiu, M., Wang, J., Gao, Y., & Li, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01599-6 · Cited by 68
An update on emerging drugs in osteosarcoma: towards tailored therapies?
Hattinger, C. M., Patrizio, M. P., Magagnoli, F., Luppi, S., & Serra, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1654455 · Cited by 67
Signaling from RAS to RAF: The Molecules and Their Mechanisms
Jeon, H., Tkacik, E., & Eck, M. J. (2024) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052521-040754 · Cited by 64
Transforming targeted cancer therapy with PROTACs: A forward-looking perspective
Farnaby, W., Koegl, M., McConnell, D. B., & Ciulli, A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.02.009 · Cited by 66
Detection of alternative DNA structures and its implications for human disease
Matos-Rodrigues, G. E., Hisey, J. A., Nussenzweig, A., & Mirkin, S. M. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.08.018 · Cited by 66
Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
Picco, G., Rao, Y., Saedi, A. A., Lee, Y., Vieira, S. F., Bhosle, S. G., May, K., Herranz, C., Walker, S. J., Shenje≠, R., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0052 · Cited by 72
Self-citationGenome-wide interrogation of gene functions through base editor screens empowered by barcoded sgRNAs
Xu, P., Liu, Z., Liu, Y., Ma, H., Xu, Y., Bao, Y., Zhu, S., Cao, Z., Wu, Z., Zhou, Z. L., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00944-1 · Cited by 66
Machine learning prediction of oncology drug targets based on protein and network properties
Dezső, Z., & Ceccarelli, M. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-3442-9 · Cited by 68
DORGE: Discovery of Oncogenes and tumoR suppressor genes using Genetic and Epigenetic features
Lyu, J., Li, J. J., Su, J., Peng, F., Chen, Y. E., Ge, X., & Li, W. (2020) · Science Advances · doi:10.1126/sciadv.aba6784 · Cited by 62
Rottner, A. K., Ye, Y., Navarro‐Guerrero, E., Rajesh, V., Pollner, A., Bevacqua, R. J., Yang, J., Spigelman, A. F., Baronio, R., Bautista, A., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01261-2 · Cited by 63
Anvar, N. E., Lin, C., Ma, X., Wilson, L., Steger, R., Sangree, A. K., Colic, M., Wang, S. H., Doench, J. G., & Hart, T. (2024) · Nature Communications · doi:10.1038/s41467-024-47795-3 · Cited by 62
State of the art CRISPR-based strategies for cancer diagnostics and treatment
Carlo, E. D., & Sorrentino, C. (2024) · Biomarker Research · doi:10.1186/s40364-024-00701-x · Cited by 69
Durinikova, E., Buzo, K., & Arena, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01981-z · Cited by 61
Base editing screens define the genetic landscape of cancer drug resistance mechanisms
Coelho, M. A., Strauß, M. E., Watterson, A., Cooper, S., Bhosle, S. G., Illuzzi, G., Karakoç, E., Dinçer, C., Vieira, S. F., Sharma, M., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01948-8 · Cited by 65
Self-citationWu, M., Huang, W., Yang, N., & Liu, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00347-1 · Cited by 59
CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment
Xing, H., & Meng, L. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0322-9 · Cited by 61
Álvarez‐Álvarez, M. M., Biayna, J., & Supek, F. (2022) · Nature Communications · doi:10.1038/s41467-022-32285-1 · Cited by 60
Targeting synthetic lethal paralogs in cancer
Ryan, C. J., Mehta, I., Kebabci, N., & Adams, D. J. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.02.002 · Cited by 59
Imkeller, K., Ambrosi, G., Boutros, M., & Huber, W. K. (2020) · Genome biology · doi:10.1186/s13059-020-1939-1 · Cited by 58
Discovering and validating cancer genetic dependencies: approaches and pitfalls
Lin, A., & Sheltzer, J. M. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0247-7 · Cited by 59
High-fidelity SaCas9 identified by directional screening in human cells
Xie, H., Ge, X., Yang, F., Wang, B., Li, S., Duan, J., Lv, X., Cheng, C., Song, Z., Liu, C., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000747 · Cited by 59
A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands
Grant, E. K., Fallon, D. J., Hann, M. M., Fantom, K. G. M., Quinn, C. J., Zappacosta, F., Annan, R. S., Chung, C., Bamborough, P., Dixon, D. P., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008361 · Cited by 59
Minimized combinatorial CRISPR screens identify genetic interactions in autophagy
Diehl, V., Wegner, M., Grumati, P., Husnjak, K., Schaubeck, S., Gubaš, A., Shah, V. J., Polat, I. H., Langschied, F., Prieto‐Garcia, C., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab309 · Cited by 55
Functional Roles of Bromodomain Proteins in Cancer
Boyson, S. P., Gao, C., Quinn, K. M., Boyd, J. R., Paculová, H., Frietze, S. E., & Glass, K. C. (2021) · Cancers · doi:10.3390/cancers13143606 · Cited by 59
A landscape of response to drug combinations in non-small cell lung cancer
Nair, N. U., Greninger, P., Zhang, X., Friedman, A. A., Amzallag, A., Cortez, E., Sahu, A. D., Lee, J. S., Dastur, A., Egan, R. K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39528-9 · Cited by 63
Self-citationPeña-Martínez, E. G., & Rodríguez‐Martínez, J. A. (2024) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1601004 · Cited by 63
Mechanisms of damage tolerance and repair during DNA replication
Ashour, M. E., & Mosammaparast, N. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab101 · Cited by 65
Li, C., Zhao, W., Pan, X., Li, X., Yan, F., Liu, S., Feng, J., & Lu, J. (2020) · Oncogene · doi:10.1038/s41388-020-01427-4 · Cited by 57
Zhao, H., Liu, Y., Wang, L., Jin, G., Zhao, X., Xu, J., Zhang, G., Ma, Y., Yin, N., & Peng, M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110083 · Cited by 57
Predicting base editing outcomes using position-specific sequence determinants
Pallaseni, A., Peets, E. M., Koeppel, J., Weller, J., Vanderstichele, T., Ho, U. L., Crepaldi, L., van Leeuwen, J. S., Allen, F., & Parts, L. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac161 · Cited by 59
Exploring liver cancer biology through functional genetic screens
Wang, C., Cao, Y., Yang, C. G., Bernards, R., & Qin, W. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00465-x · Cited by 58
Synthetic lethality between VPS4A and VPS4B triggers an inflammatory response in colorectal cancer
Szymańska, E., Nowak, P., Kolmus, K., Cybulska, M., Goryca, K., Derezińska‐Wołek, E., Szumera‐Ciećkiewicz, A., Brewińska‐Olchowik, M., Grochowska, A., Piwocka, K., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910812 · Cited by 56
Georgopoulou, D., Callari, M., Rueda, O. M., Shea, A., Martin, A. G., Giovannetti, A., Qosaj, F., Dariush, A. A., Chin, S., Carnevalli, L. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22303-z · Cited by 54
The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy
Guo, N., Liu, J., Li, W., Ma, Y., & Fu, D. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.11.018 · Cited by 64
Computational Chemistry on a Budget: Supporting Drug Discovery with Limited Resources
Willems, H. M. G., Cesco, S. D., & Svensson, F. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02126 · Cited by 56
Systematic decomposition of sequence determinants governing CRISPR/Cas9 specificity
Fu, R., He, W., Dou, J., Villarreal, O. D., Bedford, E., Wang, H. H., Hou, C., Zhang, L., Wang, Y., Ma, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28028-x · Cited by 59
Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway
Chai, A. W. Y., Yee, P. S., Price, S., Yee, S. M., Lee, H. M., Tiong, V. K., Gonçalves, E., Behan, F. M., Bateson, J., Gilbert, J. G. R., et al. (2020) · eLife · doi:10.7554/elife.57761 · Cited by 55
Self-citationMicrosatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach
Yamamoto, H., Watanabe, Y., Maehata, T., Imai, K., & Itoh, F. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02833-z · Cited by 54
Mirzaei, S., Paskeh, M. D. A., Hashemi, F., Zabolian, A., Hashemi, M., Entezari, M., Tabari, T., Ashrafizadeh, M., Raee, P., Aghamiri, S., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119948 · Cited by 52
CRISPR technology: The engine that drives cancer therapy
Zhang, M., Eshraghian, E. A., Jammal, O. A., Zhang, Z.-B., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111007 · Cited by 54
WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells
Datta, A., Biswas, K., Sommers, J. A., Thompson, H., Awate, S., Nicolae, C. M., Thakar, T., Moldovan, G., Shoemaker, R. H., Sharan, S. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26811-w · Cited by 53
Lazar, N. H., Çelik, S., Chen, L., Fay, M. M., Irish, J. C., Jensen, J., Tillinghast, C. A., Urbanik, J., Bone, W. P., Roberts, G. H. L., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01758-y · Cited by 52
Hu, M., Fu, X., Si, Z., Li, C., Sun, J., Du, X., & Zhang, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01245 · Cited by 52
Chromatin Looping Shapes KLF5-Dependent Transcriptional Programs in Human Epithelial Cancers
Liu, Y., Guo, B., Aguilera-Jimenez, E., Chu, V. S., Zhou, J. R., Wu, Z., Francis, J. M., Yang, X., Choi, P. S., Bailey, S. D., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1287 · Cited by 53
Metadata
- Authors
- Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., Ansari, R., Harper, S., Jackson, D. A., McRae, R., Pooley, R., Wilkinson, P., van der Meer, D., Dow, D., Buser-Doepner, C., Bertotti, A., Trusolino, L., Stronach, E. A., Saez-Rodriguez, J., Yusa, K., & Garnett, M. J.
- Affiliations
- Wellcome Sanger Institute (GB)
- European Bioinformatics Institute (GB)
- Candiolo Cancer Institute (IT)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- Kyoto University (JP)
- Corresponding author
- Yusa, Kosuke
- Garnett, Mathew J.
- ORCID
- Venue
- Nature
- Published
- 2019-04-10
- Volume
- 568
- Issue
- 7753
- Pages
- 511-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2936686072
- Cited by
- 1,338
- References
- 64
- Citations by year
- 2026: 129 · 2025: 168 · 2024: 200 · 2023: 158 · 2022: 200 · 2021: 227 · 2020: 179 · 2019: 74
- FWCI
- 56.69
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Wellcome Trust (C44943/A22536, SU2C-AACR-DT1213, 102696, 206194)
- Cancer Research UK (A22536, SU2C-AACR-DT1213, 102696, C44943/A22536)
- Associazione Italiana per la Ricerca sul Cancro (5X 1000, 21091, 20697, 18532)
- Stand Up To Cancer (SU2C-AACRDT1213)
- H2020 European Research Council (724748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- cancer cell lines, synthetic lethality, microsatellite instability, cancer dependency, genomic biomarkers, anticancer drug development
- MeSH terms
- Werner Syndrome Helicase, Synthetic Lethal Mutations, Gene Editing, Animals, Female, Humans, Neoplasm Transplantation, Neoplasms, Organ Specificity, Biomarkers, Tumor, Werner Syndrome, Reproducibility of Results, Genome, Human, Cell Line, Tumor, Mice, Microsatellite Instability, Drug Discovery, Molecular Targeted Therapy, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
